Sudarshan Pharma Industries has announced the establishment of a fully owned subsidiary in Poland, marking a strategic milestone in the company's European market expansion plans. This development represents a significant step forward in the pharmaceutical company's international growth strategy.

Strategic European Expansion

The establishment of the Poland subsidiary demonstrates Sudarshan Pharma Industries' commitment to strengthening its presence in the European pharmaceutical market. Poland serves as a strategic location for accessing broader European markets and establishing a stronger foothold in the region.

Market Positioning

The Poland subsidiary positions Sudarshan Pharma Industries to better serve European customers and expand its pharmaceutical operations across the continent. This move aligns with the company's broader strategy to diversify its geographical presence and reduce dependence on domestic markets.

Business Implications

The establishment of this European subsidiary reflects the company's confidence in international market opportunities and its ability to execute cross-border expansion strategies. The Poland location provides access to European Union markets and regulatory frameworks, potentially facilitating broader regional growth initiatives.

This strategic development marks an important phase in Sudarshan Pharma Industries' evolution from a domestic-focused pharmaceutical company to one with international operations and market presence.

Sudarshan Pharma Industries Limited has announced a postal ballot process to seek shareholder approval for the appointment of Dr. Vijay Ojha as Non-Executive Independent Director. The company issued the notice on December 9, 2025, with the cut-off date for eligible voting set as December 5, 2025.

Director Appointment Details

Dr. Vijay Ojha was initially appointed as Additional Director (Non-Executive Independent) on October 18, 2025, based on the recommendation of the Nomination Remuneration Committee. The postal ballot seeks formal shareholder approval for his appointment as Independent Director for a five-year term.

Professional Background

Dr. Vijay Ojha brings over 30 years of industrial experience in the pharmaceutical sector, specifically in API and formulation development, scale-up commercialization. He holds a Doctorate of Philosophy (PhD) from Central Drug Research Institute, Lucknow. His professional experience includes associations with prominent pharmaceutical companies such as Lupin Limited, Sun Pharmaceuticals Limited, IPCA Laboratories Limited, and Flavine Inc., USA.

E-Voting Process and Timeline

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. The voting process will be conducted entirely through electronic means, with no physical postal ballot forms being distributed.

Compliance and Governance

The postal ballot notice has been sent electronically to all members whose email addresses are registered with the company or depositories. Mr. Vishal Manseta (Membership No.: 25183, COP No.: 8981), Company Secretary in Practice, has been appointed as Scrutinizer for conducting the postal ballot process.

Dr. Ojha has submitted declarations confirming his independence as per Section 149(6) of the Companies Act, 2013, and Regulation 16(1)(b) of SEBI Listing Regulations. He currently holds no directorships in other companies and has no shareholding in Sudarshan Pharma Industries.

Committee Memberships

Upon appointment, Dr. Ojha will serve as a member of key board committees:

• Stakeholders Relationship Committee
• Nomination Remuneration Committee

The board considers Dr. Ojha's appointment desirable and in the company's interest, given his extensive pharmaceutical industry experience and expertise in API and formulation development.